Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab.
Kollmannsberger
C
C
Pressler
H
H
Mayer
F
F
Kanz
L
L
Bokemeyer
C
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D018734:Genes, erbB-2 / Q000235:genetics*; D018237:Germinoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab; D002945:Cisplatin